Ignite Creation Date:
2024-05-06 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04722640
Status:
UNKNOWN
Last Update Posted:
2021-01-29
First Post:
2021-01-20
Brief Title:
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
Sponsor:
Istituto Clinico Humanitas
Organization:
Istituto Clinico Humanitas
Study Overview
Official Title:
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PSORIASI_RISA
Brief Summary:
Approximately 80 patients affected by moderate to severe psoriasis will be screened for the presence of LL37 and ADAMTSL5 autoreactive T-cells in their blood at Day 0 Patients whose lymphocytes reacted with proliferation to LL37 or ADAMTSL5 will receive SKYRIZI Risakizumab at Day 1 week 4 16 28 40 LL37 and ADAMTSL5-specific T-cell responses will be evaluated at Day 0 week 16 week 28 and week 52 Each patient will be followed for 52 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None